Multiple myeloma drugs fall into various drug classes, including proteasome inhibitors (PIs), immunomodulatory drugs (IMiDs), alkylating agents, corticosteriods, histone deactylase inhibitors (HDACs), bisphophonates, and monoclonal antibodies (MAbs). In this section, a chart breaks down these medications according to their drug class. Also included is a timeline showing when each drug became FDA-approved as well as a guide to the generic, brand, and other alternate names for various drugs.
Classes: Mides, Mibs, MAbs and Others to Treat Multiple Myeloma
| Drug Class | Name | Abbreviations | Brand |
| Proteasome inhibitors | ixazomib | I | Ninlaro® |
| carfilzomib | cfz, car, K | Kyprolis® | |
| bortezomib | btz, bor, V | Velcade® | |
| Immunomodulators | pomalidomide | pom, P | Pomalyst® |
| lenalidomide | len, R | Revlimid® | |
| thalidomide | thal, T | Thalomid® | |
| Alkylating agents | melphalan | mel, M | Alkeran®, Alphalan® |
| cyclophosphamide | CTX, Cy, C | Cytoxan® | |
| bendamustine | Treanda® | ||
| Corticosteroids | dexamethasone | D, d, dex, DXM | Decadron® |
| prednisone | pred, P | Delatsone® | |
| methylprednisolone | none yet | Medrol® | |
| Histone Deactylase Inhibitors | panobinostat | none yet | Farydak® |
| Bone-modifying agents | denosumab | none yet | Xgeva® |
| zoledronic acid | zol | Zometa® | |
| pamidronate | pmd | Aredia® | |
| Monoclonal antibodies | daratumumab | dara | Darzalex® |
| elotuzumab | elo, E | Empliciti® | |
| XP01 inhibitor | selinexor | none yet | Xpovio® |
Myeloma Drug Timeline
Guide to Drug Names
| GENERIC NAME | BRAND NAME | ORIGINAL NAME |
|---|---|---|
|
afuresertib |
GSK2110183 |
|
|
bendamustine |
Treanda® |
SDX-105 |
| bortezomib |
Velcade® |
PS-341 |
|
carfilzomib |
Kyprolis® |
PR-171 |
|
cyclophosphamide |
Cytoxan® |
|
|
dabrafenib |
Tafinlar® |
|
|
daratumumab |
Darzalex® |
CD38 mAb |
|
dasatinib |
Sprycel® |
BMS-354825 |
|
denosumab |
XGEVA® |
AMG-162, osteoprotegerin |
|
dinaciclib |
SCH 727965 |
|
|
durvalumab |
MED14736 |
|
|
eltrombopag |
Promacta® |
|
|
elotuzumab |
Empliciti® |
HuLuc63 |
|
everolimus |
Afinitor® |
LY317615 |
|
filanesib |
ARRY-520 |
|
|
Ibrutinib |
Imbruvica® |
PCI-32765 |
|
indatuximab ravtansine |
BT062 |
|
|
ipilumumab |
Yervoy® |
|
|
ixazomib |
Ninlaro® |
MLN9708 |
|
lenalidomide |
Revlimid® |
CC-5013 |
|
lirilumab |
IPH-2102, BMS-986015 |
|
|
marizomib |
NPI-0052, salinosporamide |
|
|
masitinib |
AB1010 |
|
|
melphalan |
Alkeran® |
|
|
nelfinavir |
Viracept® |
|
|
nivolumab |
Opdivo® |
BMS-936558 |
|
oprozomib |
ONX-0912 |
|
|
palbociclib |
Ibrance® |
PD 0332991 |
|
pamidronate |
Aredia® |
|
|
panobinostat |
Farydak® |
LBH589 |
|
pegylated liposomal doxorubicin |
Doxil® |
|
|
pembrolizumab |
Keytruda® |
MK-3475-013 |
|
pidilizumab |
CT-011 |
|
|
plerixafor |
Mozobil® |
AMD3100 |
|
plitidepsin |
Aplidin® |
|
|
pomalidomide |
Pomalyst® |
CC-4047 |
|
quisinostat |
JNJ26481585 |
|
|
ricolinostat |
ACY-1215 |
|
|
romidepsin |
Istodax® |
FK228, depsipeptide |
|
selinexor |
Xpovio® |
KPT-330 |
|
sirolimus |
Rapamune® |
rapamycin, AY 22989 |
|
sonidegib |
Odomzo® |
LDE225, erismodegib |
|
sotatercept |
ACE-011 |
|
|
temsirolimus |
Torisel® |
CCI-779 |
|
thalidomide |
Thalomid® |
|
|
trametinib |
Mekinist® |
GSK11202 |
|
ulocuplumab |
BMS-936564 |
|
|
urelumab |
BMS-663513 |
|
|
venetoclax |
Venclexta® |
ABT-199 |
|
vorinostat |
Zolinza® |
SAHA |
|
zoledronic acid, zoledronate |
Zometa® |
The International Myeloma Foundation medical and editorial content team
Comprised of leading medical researchers, hematologist/oncologists, oncology-certified nurses, medical editors, and medical journalists, our team has extensive knowledge of the multiple myeloma treatment and care landscape. Additionally, Dr. Brian G.M. Durie reviews and approves all medical content on this website.
Last Medical Review: August 15, 2019